About
Jeff is a deal lawyer with a broad transactional practice focused exclusively on the life sciences industry.
Jeff represents a wide range of clients—including multinational pharmaceutical companies, biotechs, private equity portfolio companies, and other players in the life sciences ecosystem—on their most strategic transactions, spanning complex licensing and collaboration and M&A matters. He also frequently advises on operational agreements such as supply, distribution, research, and IP license agreements, both on a standalone basis and in the context of larger deals.
Jeff began his career as a patent litigator and regularly leverages his substantive IP experience in his practice. He also previously worked in Freshfields’ London office.
Additional Information
Licensing & Collaboration Transactions
- Novartis on numerous transactions, including its strategic collaboration with Monte Rosa Therapeutics regarding the development of novel degraders for immune-mediated diseases; its strategic collaboration with Vyriad regarding the discovery and development of in vivo chimeric antigen receptor (CAR) T-cell therapies; its co-development and co-commercialization agreement with UCB regarding disease-modifying therapies for Parkinson’s Disease; its collaboration with Cellular Biomedicine Group regarding the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China; its collaboration with Mesoblast regarding remestemcel-L for the treatment of acute respiratory distress syndrome; and its collaboration with Sangamo Therapeutics regarding gene regulation therapies directed to neurodevelopmental targets.
- SERB Pharmaceuticals on its license from SFJ Pharmaceuticals to obtain exclusive U.S. rights to bentracimab, a ticagrelor reversal agent.
- Camurus on its collaboration with Eli Lilly for the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health based on Camurus’ FluidCrystal technology.
- Moderna on its collaboration with CARsgen Therapeutics for the development of a combination therapy consisting of an mRNA-based cancer vaccine and an autologous CAR-T therapy.
- Capsida Biotherapeutics on its collaboration with Prevail Therapeutics regarding CNS gene therapies.
- Spark Therapeutics on its collaboration with Senti Biosciences regarding gene therapies directed to specific cell types in the central nervous system, eye, and liver.
- Gilead Sciences on its collaboration with Agenus regarding novel immuno-oncology therapies; its collaboration with Hookipa Biotech regarding immunotherapies directed against hepatitis B virus and human immunodeficiency virus; its collaboration with Tango Therapeutics regarding cancer immunotherapies; and its license with Xencor regarding effector-enhanced, broadly neutralizing anti-HIV antibodies.
- Celgene on the restructuring of its collaboration with Jounce Therapeutics regarding immuno-oncology therapies.
- A global pharmaceutical company on its collaboration with a clinical-stage biotechnology company regarding the use of proprietary gene editing technologies to design novel cell and gene therapy product candidates.
- A clinical-stage biotechnology company on its license agreement with a U.S. university regarding the treatment of certain metabolic disorders.
- A global pharmaceutical company on its divestment of China rights to a pharmaceutical product for the treatment of certain esophageal, gastrointestinal, and pancreatic disorders.
M&A Transactions
- Novartis on numerous transactions, including its acquisitions of AveXis, Cadent Therapeutics, IFM Tre, Mariana Oncology, MorphoSys AG, and Vedere Bio, and its option to acquire IFM Due.
- Roivant Sciences on its $7.1 billion sale of Telavant to Roche and its sale of Dermavant to Organon for up to $1.2 billion.
- SERB Pharmaceuticals on its acquisition of RSDL® (Reactive Skin Decontamination Lotion) kit from Emergent BioSolutions and its take-private of Y-mAbs Therapeutics.
- AstraZeneca on its acquisition of Gracell Biotechnologies.
- Basilea Pharmaceutica on its acquisition from Pfizer of Fosmanogepix, a clinical-stage antifungal candidate with a novel mechanism of action to treat invasive mold infections.
- Convatec Group on its acquisition of an innovative antimicrobial nitric oxide platform from 30 Technology.
- Recordati, a portfolio company of CVC Capital Partners, on its acquisition of EUSA Pharma (UK) Limited.
- Celgene on its acquisition of Juno Therapeutics.
- Kite Pharma, a Gilead company, on its option to acquire, and related strategic collaboration with, Gadeta B.V.
- Bausch Health on its option to acquire certain assets of Allegro Ophthalmics.
- Jazz Pharmaceuticals on its acquisition of Cavion.
- A global specialty pharmaceutical company on its acquisition of a commercial-stage product for the treatment of certain severe injuries.
- A biotechnology company on its acquisition of a clinical-stage, private biotechnology company focused on the development of CAR T-therapies.
- A contract development and manufacturing organization on the sale of its generic pharmaceuticals business to an Indian pharmaceutical company.
- A global pharmaceutical company on its acquisition of a priority review voucher.
Jeff Jay
Partner
New York Office
3 World Trade Center
175 Greenwich Street, 51st Floor
New York 10007